Carbidopa monohydrate 38821-49-7

98% up by HPLC, USP39

Product categories

New Products

Product Details

Product Information

Product name	Carbidopa monohydrate
Alias	Benzenepropanoicacid, a-hydrazino-3,4-dihydroxy-a-methyl-, monohydrate, (S)-;Benzenepropanoic acid, a-hydrazino-3,4-dihydroxy-a-methyl-, monohydrate, (aS)- (9CI);
CAS No.	38821-49-7
Molecular Formula	C10H14N2O4*H2O
Molecular Weight	244.247
Molecular Structure
Quality Standard	98% up by HPLC
Appearance	White to creamy white powder

COA

ANALYSIS	SPECIFICATION	RESULTS
Appearance	White to creamy white powder	Conform
Solubility	Slightly soluble in water, freely soluble in 3 N hydrochloric acid, slightly soluble in methanol, practically insoluble in alcohol, in acetone, in chloroform, and in ether.	Conform
Identification	IR: The spectrum of sample corresponds to that of the ref. standard.	Conform
Identification	HPLC: The retention time of sample of main peaks corresponds to that of the ref. standard.	Complies
Specific rotation	-21°～ -23.5°	-21.8°
Loss on drying	6.9% ～ 7.9%	7.2%
Residue on ignition	≤ 0.1%	0.05%
Heavy metals	≤ 0.001%	< 0.001%
Methyldopa	≤0.5%	0.1%
Carbidopa related compound A	≤0.5%	Negative
Any other impurity	≤0.1%	0.01%
Total impurities	≤1.0%	0.13%
Residual solvents	Should conform	Conform
Assay	98.0% - 102.0%	99.6%
Conclusion	The results above meet the requirements of USP39

Usage

What is Carbidopa?

Parkinson’s disease is a degenerative condition that affects the central nervous system and causes difficulties controlling movements and impairs muscle function. It is thought to perhaps be the result of abnormally low levels of dopamine, a chemical in the brain that is responsible for a variety of functions, including controlling the body’s movement. The medication is typically only effective at treating Parkinson’s disease when it is combined with another drug known as levodopa. Carbidopa is a medication that is primarily used in treating the symptoms of Parkinson’s disease.

Levodopa and carbidopa usually work together at treating the symptoms of Parkinson’s disease in a process. Since Parkinson’s disease is thought to be the result of low levels of dopamine, levodopa may help decrease Parkinson’s disease symptoms, such as tremors, stiffness, and muscle spasms, by increasing the amounts of dopamine in the body. When levopoda is taken, it turns into dopamine; however, the medication risks being metabolized by the body in the bloodstream before it can reach the brain as dopamine and effectively treat Parkinson’s disease symptoms. Carbidopa may help slow down the metabolizing of levopoda so that it has time to be released as dopamine in the brain, rather than being absorbed into the bloodstream.

*Products under the patent are only for R&D use